Low-dose aspirin cuts colon cancer recurrence in trial
Source: scitechdaily.com Key Points: Aspirin reduces colon cancer and rectal cancer recurrence in PI3K mutation patients. recurrence in PI3K mutation patients. ALASCCA trial tested low-dose aspirin in 3,500+ patients across four countries. Aspirin’s low cost makes it a global option for colorectal cancer care. A daily low dose of aspirin reduced the risk of colon and rectal cancer recurrence by more than half in certain patients, according to results from a large clinical trial led by Karolinska Institutet and Karolinska University Hospital. The study, confirming that Aspirin Reduces Colon Cancer recurrence in genetically defined patients, was published Sept. 17 in The New England Journal of Medicine. Trial across four countries The randomized ALASCCA trial enrolled more than 3,500 patients at 33 hospitals in Sweden, Norway, Denmark, and Finland. Researchers focused on patients whose tumors carried a mutation in the PI3K signaling pathway, a genetic alteration present in about 40...